Fig. 5

Effect of GCSW210 on cell cytotoxicity and glucose uptake in DEX-mediated insulin resistance model of L6 myotubes. A) cytotoxicity produced by DEX; B) glucose uptake measured at various concentrations of DEX; C) cytotoxicity after GCSW210 treatment in DEX-mediated IR model; D) glucose uptake after GCSW210 treatment in DEX-mediated IR model. L6 cells were induced to differentiate with 2% HS and treated as indicated. After 24 h of treatment with 0.5 μM of DEX, L6 myotubes were further treated with 125 or 250 μg/mL of GCSW210, or with no GCSW210 added, for 24 h. Cell viability was determined using WST assay at 450 nm and glucose uptake was measured using 2-NDBG. Data are presented as mean ± SE (n = 6) and analyzed by one-way analysis of variance followed by Dunnett test. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. DEX. Abbreviations: DEX; dexamethasone, HS; horse serum, 2-NBDG; 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxyglucose.